Artiva Biotherapeutics reported a net loss of $25.0 million for the quarter ended June 30, 2026, compared to $21.3 million in the prior year period. The company holds $349.4 million in cash and investments, sufficient to fund operations into 2029. Artiva announced it will initiate a Phase 3 registrational trial for AlloNK plus rituximab in approximately 150 refractory rheumatoid arthritis patients in the second half of 2026, following FDA RMAT designation. The firm also appointed Diego Miralles as president and head of R&D. Artiva Biotherapeutics is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases.